These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18848138)

  • 1. What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?
    Bhatt DL
    J Am Coll Cardiol; 2008 Sep; 52(13):1060-1. PubMed ID: 18848138
    [No Abstract]   [Full Text] [Related]  

  • 2. Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients.
    Koltai K; Feher G; Kenyeres P; Lenart I; Alexy T; Horvath B; Marton Z; Kesmarky G; Toth K
    Clin Hemorheol Microcirc; 2008; 40(4):295-302. PubMed ID: 19126992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet function testing in atherothrombotic disease: steps forward in managing resistance to antiplatelet therapy.
    Grove EL; Hvas AM; Kristensen SD
    Kardiol Pol; 2008 Apr; 66(4):478-9. PubMed ID: 19496276
    [No Abstract]   [Full Text] [Related]  

  • 4. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
    Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
    Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetics of antiplatelet drug resistance.
    Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
    Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and systemic functions of bone fat and its contribution to the energy metabolism--the effect of diabetes and obesity on bone.
    Lecka-Czernik B
    J Musculoskelet Neuronal Interact; 2008; 8(4):346-7. PubMed ID: 19147970
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet dysfunction in central obesity.
    Anfossi G; Russo I; Trovati M
    Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):440-9. PubMed ID: 19346117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiaggregant properties of new 1,3,4-thiadiazine derivatives].
    Vasil'eva TM; Makarov VA; Chupakhin ON; Sidorova LP; Perov NM; Rusinov VL
    Eksp Klin Farmakol; 2009; 72(5):27-30. PubMed ID: 19928572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine diphosphate-induced platelet aggregation correlates with platelet activation identified with the use of flow cytometry.
    García M; Schneider DJ
    Pathophysiol Haemost Thromb; 2008; 36(2):75-9. PubMed ID: 19127086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel anti-platelet aggregation tripeptide from Agkistrodon acutus venom: isolation and characterization.
    Kong Y; Huo JL; Xu W; Xiong J; Li YM; Wu WT
    Toxicon; 2009 Aug; 54(2):103-9. PubMed ID: 19345702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet and fibrinogen kinetic studies in diabetes mellitus.
    Ferguson JC; Mackay N; Philip JA; Sumner DJ
    Br J Haematol; 1973 Oct; 25(4):545. PubMed ID: 4752722
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis of 2,3-disubstituted 1,4-naphthoquinones as antiplatelet agents.
    Lien JC; Wu CR; Hour MJ; Huang LJ; Huang TF; Kuo SC
    Arch Pharm (Weinheim); 2008 Oct; 341(10):639-44. PubMed ID: 18720342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
    Manaster Y; Shenkman B; Rosenberg N; Savion N
    Thromb Res; 2009 Sep; 124(4):477-82. PubMed ID: 19632706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.
    Velik-Salchner C; Maier S; Innerhofer P; Kolbitsch C; Streif W; Mittermayr M; Praxmarer M; Fries D
    Anesth Analg; 2009 Jun; 108(6):1747-54. PubMed ID: 19448196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Physiology and pathophysiology. Fundamentals of platelet pharmacology].
    Jastrow H; Weber AA
    Pharm Unserer Zeit; 2009; 38(4):302-4. PubMed ID: 19572351
    [No Abstract]   [Full Text] [Related]  

  • 17. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Various therapy options. Medical Chemistry of platelet aggregation inhibitors].
    Zettl H; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2009; 38(4):314-9. PubMed ID: 19572349
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet antiaggregating activity of ginsenosides isolated from processed ginseng.
    Lee JG; Lee YY; Kim SY; Pyo JS; Yun-Choi HS; Park JH
    Pharmazie; 2009 Sep; 64(9):602-4. PubMed ID: 19827304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of response to antiplatelet therapy: what should we do next?
    Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Feb; 23(1):19-22. PubMed ID: 19267768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.